- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| Fr | Psyence BioMed gets Nasdaq notice for non-compliance | 1 | Seeking Alpha | ||
| Fr | Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency | 272 | Newsfile |
New York, New York--(Newsfile Corp. - April 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") announced today that it received a notification letter dated April... ► Artikel lesen | |
| Di | Psyence BioMed erhöht Beteiligung an PsyLabs mit 500.000 US-Dollar Investition | 2 | Investing.com Deutsch | ||
| Di | Psyence BioMed boosts stake in PsyLabs with $500k investment | 2 | Investing.com | ||
| Di | Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement | 180 | Newsfile | New York, New York--(Newsfile Corp. - April 15, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced a strategic follow-on investment of USD $500,000 into... ► Artikel lesen | |
| 11.04. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 08.04. | Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia | 135 | Newsfile | New York, New York--(Newsfile Corp. - April 8, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the signing of a Letter of Intent (LOI) with Southern Star Research... ► Artikel lesen | |
| 31.03. | Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing | 148 | Newsfile | New York, New York--(Newsfile Corp. - March 31, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") releases the following update:Dear Shareholders and Future Investors:At... ► Artikel lesen | |
| 31.03. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 25.03. | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein | 1 | GlobeNewswire (USA) | ||
| 18.03. | Psyence Biomed expands advisory board with psychopharmacology expert | - | Investing.com | ||
| 18.03. | Psyence Biomed erweitert Beirat mit Experten für Psychopharmakologie | 1 | Investing.com Deutsch | ||
| 18.03. | Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein | 247 | Newsfile | New York, New York--(Newsfile Corp. - March 18, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence Biomed" or the "Company") today announced that it has expanded and further strengthened its Scientific... ► Artikel lesen | |
| 10.03. | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board | 164 | GlobeNewswire (Europe) | TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM"... ► Artikel lesen | |
| 04.03. | Psyence Biomedical files to sell 13.81M common shares for holders | 1 | Seeking Alpha | ||
| 24.01. | PSYENCE BIOMEDICAL LTD. - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 23.01. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.12.24 | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.12.24 | Psyence Biomedical Ltd.: Psyence Biomed Announces Closing of $2.0 Million Private Placement | 2 | GlobeNewswire (USA) | ||
| 23.12.24 | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | - | SEC Filings |
Seite:
1 2 3 4 Weiter >>
67 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd.: BioLineRx Reports 2024 Financial Results and Provides Corporate Update | - Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases -
- Executed license... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 0,265 | -2,72 % | Transcode Therapeutics, Inc. - 10-K, Annual Report | ||
| SILEXION THERAPEUTICS | 0,754 | -0,95 % | Silexion Therapeutics Corp: Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data | Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| MINK THERAPEUTICS | 7,830 | +1,16 % | MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress | NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural... ► Artikel lesen |
Das Unternehmen PSYENCE BIOMEDICAL LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,491 Euro und damit +9,50 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.
